title: NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
authors.forename: Bernice
authors.initials: B
authors.lastname: Dillon
authors.forename: Bhash
authors.initials: B
authors.lastname: Naidoo
authors.forename: Helen
authors.initials: H
authors.lastname: Knight
authors.forename: Peter
authors.initials: P
authors.lastname: Clark
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors / Q000235:genetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000191:economics / Q000201:enzymology / Q000235:genetics / Q000401:mortality / Q000556:secondary; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D019317:Evidence-Based Medicine; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000201:enzymology / Q000235:genetics / Q000401:mortality / Q000473:pathology; D009154:Mutation; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D019057:Quality-Adjusted Life Years; D011799:Quinazolines / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors